Real World Stage II-III NSCLC Patients Receiving Neoadjuvant Chemo-immunotherapy and no Surgical Resection

RecruitingOBSERVATIONAL
Enrollment

60

Participants

Timeline

Start Date

July 16, 2024

Primary Completion Date

December 28, 2025

Study Completion Date

December 30, 2025

Conditions
Stage II-III Non-small Cell Lung Cancer
Trial Locations (1)

5262000

RECRUITING

Jusidman Cancer Center, Sheba Medical Center, Ramat Gan

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Rambam Health Care Campus

OTHER

collaborator

Soroka University Medical Center

OTHER

collaborator

Gustave Roussy, Cancer Campus, Grand Paris

OTHER

collaborator

Hadassah Medical Organization

OTHER

collaborator

Rabin Medical Center

OTHER

collaborator

University Hospital, Geneva

OTHER

collaborator

Tel-Aviv Sourasky Medical Center

OTHER_GOV

collaborator

MedStar Georgetown University Hospital

OTHER

collaborator

Mayo Clinic

OTHER

collaborator

UOMi Cancer Center

OTHER

lead

Sheba Medical Center

OTHER_GOV

NCT07131163 - Real World Stage II-III NSCLC Patients Receiving Neoadjuvant Chemo-immunotherapy and no Surgical Resection | Biotech Hunter | Biotech Hunter